751 – 760 of 2181
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Targeting Factor Replacement Therapy in Severe Hemophilia: Which Level Is Important?
(
- Contribution to journal › Article
-
Mark
Can a "center effect" explain the higher frequency of inhibitors for a second generation recombinant factor VIII product?
(
- Contribution to journal › Letter
-
Mark
Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method.
(
- Contribution to journal › Article
-
Mark
Strategies for reducing inhibitor formation in severe haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Population-based study on the impact of the familial form of Waldenström macroglobulinemia on overall survival.
(
- Contribution to journal › Letter
-
Mark
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
(
- Contribution to journal › Article
-
Mark
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.
(
- Contribution to journal › Article
-
Mark
Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network.
(
- Contribution to journal › Article
-
Mark
Ebf1 heterozygosity results in increased DNA damage in pro-B cells and their synergistic transformation by Pax5 haploinsufficiency.
(
- Contribution to journal › Article
-
Mark
The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
(
- Contribution to journal › Article